Literature DB >> 9186096

Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C.

K Singh1, P R Egbert, S Byrd, D L Budenz, A S Williams, J H Decker, P Dadzie.   

Abstract

PURPOSE: To compare the effectiveness of intraoperative 5-fluorouracil (5-FU) and mitomycin C used adjunctively with trabeculectomy in a black West African population.
METHODS: Eighty-five consecutive eyes of 85 black patients undergoing primary trabeculectomy for open-angle glaucoma were prospectively randomly assigned to receive either 5-FU (50 mg/ml for 5 minutes) or mitomycin C (0.5 mg/ml for 3 1/2 minutes) intraoperatively by soaked sponge.
RESULTS: Of the 81 eyes with at least a 3-month postoperative follow-up, 41 of 44 (93.2%) in the mitomycin C group and 27 of 37 (73.0%) in the 5-FU group had a final intraocular pressure of less than 21 mm Hg (P = .01). Twenty-eight of 44 eyes (63.6%) in the mitomycin C group and 18 of 37 (51.4%) in the 5-FU group had a final intraocular pressure of less than 15 mm Hg (P = .26). Mean postoperative intraocular pressure was 13.7 mm Hg in the mitomycin C group and 16.3 mm Hg in the 5-FU group (P = .05). There were no differences between the two groups in mean age, preoperative intraocular pressure, postoperative visual acuity, and complications. Mean follow-up was 10.0 +/- 4.41 months (range, 4 to 19 months).
CONCLUSIONS: The adjunctive use of mitomycin C with trabeculectomy is equally safe and more efficacious compared to 5-FU in this West African population. Use of mitomycin C in this study was not associated with a statistically significantly greater proportion of patients achieving low intraocular pressure (less than 15 mm Hg) compared to 5-FU.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186096     DOI: 10.1016/s0002-9394(14)70991-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  24 in total

1.  Towards better treatment of glaucoma.

Authors:  P T Khaw; M F Cordeiro; M F Cordiero
Journal:  BMJ       Date:  2000-06-17

Review 2.  Glaucoma in West Africa: a neglected problem.

Authors:  Peter R Egbert
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

3.  How to manage a patient with glaucoma in Africa.

Authors:  Richard Jc Bowman; Subramaniam Kirupananthan
Journal:  Community Eye Health       Date:  2006-09

4.  Antifibrotic effects of pirfenidone on Tenon's fibroblasts in glaucomatous eyes: comparison with mitomycin C and 5-fluorouracil.

Authors:  Jung Hwa Na; Kyung Rim Sung; Jin A Shin; Jung Il Moon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-07       Impact factor: 3.117

5.  Comparison of fornix- and limbus-based conjunctival flaps in mitomycin C trabeculectomy with laser suture lysis in Japanese glaucoma patients.

Authors:  Takeo Fukuchi; Jun Ueda; Kiyoshi Yaoeda; Kieko Suda; Masaaki Seki; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

6.  Long term results of glaucoma surgery among participants in an east African population survey.

Authors:  H A Quigley; R R Buhrmann; S K West; I Isseme; M Scudder; M S Oliva
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

7.  A randomised trial of the effect of intraoperative 5-FU on the outcome of trabeculectomy in east Africa.

Authors:  D Yorston; P T Khaw
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

Review 8.  The clinical applications of fluorouracil in ophthalmic practice.

Authors:  Lekha M Abraham; Dinesh Selva; Robert Casson; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Deep sclerectomy and low dose mitomycin C: a randomised prospective trial in west Africa.

Authors:  C Mielke; V K Dawda; N Anand
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

10.  National survey of antimetabolite use in glaucoma surgery in the United Kingdom.

Authors:  D Siriwardena; B Edmunds; R P L Wormald; P T Khaw
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.